GS
IMA

Gilead Sciences’s ImageneBio Inc IMA Stock Holding History

Gilead Sciences’s Portfolio IMA Stock Details IMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,045
Closed -$467K – 13
2025
Q2 		$467K Sell
29,045
-67,550
-70% -$992K 0.04% 13
2025
Q1 		$1.48M Sell
96,595
-70,767
-42% -$1.22M 0.13% 13
2024
Q4 		$3.29M Buy
+167,362
New +$3.38M 0.21% 12

Other funds holding IMA

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Gilead Sciences's IMA Position: Q3 2025 in Review

Gilead Sciences sold out of ImageneBio Inc (IMA) in Q3 2025, closing a stake of 29,045 shares — an estimated $467K sold.

Gilead Sciences first reported a position in IMA in Q4 2024 and held it in 3 quarters. The position peaked at $3.29M in Q4 2024. 33 funds tracked by Wall St. Rank hold IMA as of Q3 2025.

  • Gilead Sciences reported no remaining ImageneBio Inc position as of Q3 2025 after selling out during the quarter.
  • Gilead Sciences sold 29,045 ImageneBio Inc shares in Q3 2025, an estimated $467K.
  • Gilead Sciences first reported a position in ImageneBio Inc in Q4 2024 and held it in 3 quarters.
  • Gilead Sciences's ImageneBio Inc position peaked at $3.29M in Q4 2024.
  • 33 funds tracked by Wall St. Rank held ImageneBio Inc as of Q3 2025.

Based on Gilead Sciences's 13F filing for Q3 2025, filed 13 Nov 2025.